Antibody Response to SARS-CoV-2 Vaccination in Patients With Lymphoproliferative Disorders and Plasma Cell Dyscrasias: Anti-Lymphoma Therapy as a Predictive Biomarker of Response to Vaccination.

Saved in:

Bibliographic Details
Title:	Antibody Response to SARS-CoV-2 Vaccination in Patients With Lymphoproliferative Disorders and Plasma Cell Dyscrasias: Anti-Lymphoma Therapy as a Predictive Biomarker of Response to Vaccination.
Authors:	Gung C; Division of Hematologic Malignancies, Department of Medical Oncology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United States., McGuire R; Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United States., George M; Division of Hematologic Malignancies, Department of Medical Oncology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United States., Abdulkareem A; Division of Hematologic Malignancies, Department of Medical Oncology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United States., Belden KA; Division of Infectious Diseases, Department of Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United States., Porcu P; Division of Hematologic Malignancies, Department of Medical Oncology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United States., Martinez-Outschoorn U; Division of Hematologic Malignancies, Department of Medical Oncology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United States., Binder AF; Division of Hematologic Malignancies, Department of Medical Oncology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United States., Chervenova I; Division of Biostatistics, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United States., Alpdogan O; Division of Hematologic Malignancies, Department of Medical Oncology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United States.
Source:	Frontiers in oncology [Front Oncol] 2022 Jul 07; Vol. 12, pp. 840451. Date of Electronic Publication: 2022 Jul 07 (Print Publication: 2022).
Publication Type:	Journal Article
Journal Info:	Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	2234-943X
DOI:	10.3389/fonc.2022.840451